Alport Connect 2025 Meeting
19-20 July, 2025
Chicago, IL
ENYO Pharma is sponsoring and will attend Alport Connect 2025 organized by the American Alport Syndrome Foundation (ASF), the Alport syndrome patient-led non-profit organization in the US.
ENYO Pharma will meet patients and their families to present its ongoing Phase 2 “ALPESTRIA-1” clinical study with Vonafexor in Alport syndrome patients.
BIO International Convention
16-19 June, 2025
Boston, MA
ENYO Pharma will attend the the BIO International Convention, the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.
https://convention.bio.org/bio-2025
ENYO Pharma announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- ENYO Pharma completes €32 million Series C with new €6 million investment from Vesalius Biocapital IV
- New funds will support two additional clinical studies and expand preclinical research, including in ADPKD
- Topline results from its ALPESTRIA-1 Phase 2 trial of Vonafexor in Alport syndrome confirmed for Q4 2025
Lyon, France – June 12, 2025
ENYO Pharma (“ENYO”), a clinical-stage biotechnology company focused on developing FXR agonists for the treatment of severe kidney diseases,
Enrollment completed for our Phase 2 clinical trial in Alport syndrome
ENYO Pharma is very proud to announce the successful completion of patient enrollment in ALPESTRIA-1, our Phase 2 clinical trial evaluating Vonafexor in Alport syndrome across the U.S. and Europe.
This major milestone was achieved with the last-patient-in dosed ahead of schedule. The study timelines were accelerated thanks to a tailored strategy based on a very strong and effective collaboration with our partners Natera and Accelsiors, all clinical sites in the US, France ans Spain with investigators,
7th CKD Summit – Chronic Kidney Disease Drug Development
17-19 March, 2025
Boston, MA
ENYO Pharma will attend the 7th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.
https://ckd3-summit.com/
Latest Press Release 